Technology allows analysis in whole tissue sections and tissue microarrays.
HistoRx’ PM-2000™ image analyzer platform instrument has been installed in four oncology research institutions: Brigham and Women’s Hospital, Mayo Clinic, H. Lee Moffitt Cancer Center & Research Institute, and University of Wisconsin-Madison, School of Medicine and Public Health, Department of Pathology. Each has the right to use the HistoRx Aqua® (Automated Quantitative Analysis) biomarker analysis technology platform under the HistoRx Academic Research HARP™ Program, under the noncommercial technology licensing agreements between them and the company.

“The rapid uptake of the Aqua technology by these preeminent cancer research institutions affirms its value as a critical new discovery research and clinical development tool,” points out John L. Tonkinson, vp of business development at HistoRx.

Aqua technology allows quantification, molecular spatial resolution, and reproducibility to in situ biomarker analysis in cell samples, whole tissue sections, and tissue microarrays, explains HistoRx. The technology is at the core of the fluorescence microscopy-based PM-2000, which enables pathologists to measure the subcellular localization and relative concentration of multiple clinically relevant proteins in diseased tissue to guide drug development and therapeutic decision making.

“With this new technology,” explains Gerold Bepler, M.D., Ph.D., thoracic program director at the Moffitt Cancer Center, “we are able to analyze the state of protein signaling pathways and complex proteomic patterns in disease-altered tissue, providing the information we need to reliably subclassify disease and predict therapeutic response to specific drugs.”

Previous articleSchering-Plough Contracts with OncoMethylome Sciences for Use of MGMT Methylation Testing
Next articleLonza Makes Its Largest Acquisition: Cambrex’ Bio Businesses for $460M